CSA

CSA

CSA

Monitoring and reviewing clinical trial data is critical for any clinical development plan. But today’s manual processes often result in errors, compromising data quality and incurring costly study delays. Medidata Centralized Statistical Analytics (CSA) provides immediate insight into site performance and data quality, making it easier to detect and track critical changes throughout the trial. CSA also integrates data from different systems and provides a comprehensive report for each subject.

Enabling more insightful clinical trial reviews

Monitoring and reviewing clinical trial data is a critical step to ensuring the success of any clinical development plan. But today’s manual processes can often result in errors, compromising data quality and incurring costly study delays.

Medidata Centralized Statistical Analytics (CSA) provides immediate insight into clinical trial site performance and data quality. An integral part of Medidata Clinical Cloud, CSA integrates data from different systems and provides a comprehensive report for each subject, making it easier for teams to detect and track critical data changes throughout trial execution. 

The advanced and robust statistical algorithms in Medidata CSA provide a comprehensive scan of a clinical trial database for inconsistencies across data domains, sites and patients. With templates for SDTM data, automated processes can be setup so that every clinical study submitted to the FDA can have a study grade calculated for data quality. The overall study grade can be a measure of overall data consistency, and be compared across sponsors, studies, indications and disease areas. Individual site grades can be used to measure data quality within the site, and identify studies and sites at high-risk for procedural problems and data errors.

Get Started

Medidata’s services team and Services Partners can help get your trial up and running quickly.

Quickly gain know-how in the platform through Medidata Academy’s extensive courses and flexible training formats.

Questions? Contact us.